Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Handle, F; Puhr, M; Gruber, M; Andolfi, C; Schäfer, G; Klocker, H; Haybaeck, J; De, Wulf, P; Culig, Z.
The Oncogenic Protein Kinase/ATPase RIOK1 Is Up-Regulated via the c-myc/E2F Transcription Factor Axis in Prostate Cancer.
Am J Pathol. 2023; 193(9):1284-1297 Doi: 10.1016/j.ajpath.2023.05.013
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Haybäck Johannes
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: The atypical protein kinase/ATPase RIO kinase (RIOK)-1 is involved in pre-40S ribosomal subunit production, cell-cycle progression, and protein arginine N-methyltransferase 5 methylosome substrate recruitment. RIOK1 overexpression is a characteristic of several malignancies and is correlated with cancer stage, therapy resistance, poor patient survival, and other prognostic factors. However, its role in prostate cancer (PCa) is unknown. In this study, the expression, regulation, and therapeutic potential of RIOK1 in PCa were examined. RIOK1 mRNA and protein expression were elevated in PCa tissue samples and correlated with proliferative and protein homeostasis-related pathways. RIOK1 was identified as a downstream target gene of the c-myc/E2F transcription factors. Proliferation of PCa cells was significantly reduced with RIOK1 knockdown and overexpression of the dominant-negative RIOK1-D324A mutant. Biochemical inhibition of RIOK1 with toyocamycin led to strong antiproliferative effects in androgen receptor-negative and -positive PCa cell lines with EC₅₀ values of 3.5 to 8.8 nmol/L. Rapid decreases in RIOK1 protein expression and total rRNA content, and a shift in the 28S/18S rRNA ratio, were found with toyocamycin treatment. Apoptosis was induced with toyocamycin treatment at a level similar to that with the chemotherapeutic drug docetaxel used in clinical practice. In summary, the current study indicates that RIOK1 is a part of the MYC oncogene network, and as such, could be considered for future treatment of patients with PCa.
Find related publications in this database (using NLM MeSH Indexing): Male - administration & dosage; Humans - administration & dosage; Genes, myc - administration & dosage; Protein Kinases - genetics; Adenosine Triphosphatases - genetics, metabolism, pharmacology; Toyocamycin - pharmacology, therapeutic use; Cell Proliferation - administration & dosage; Prostatic Neoplasms - pathology; E2F Transcription Factors - genetics, metabolism; Cell Line, Tumor - administration & dosage; Gene Expression Regulation, Neoplastic - administration & dosage